Clinical InvestigationInterventional CardiologyComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT)
Section snippets
Study design and patients
ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using OCT (COVER OCT) is a prospective, multicenter study to investigate the vascular healing pattern of EES (Xience V, Abbott Vascular, Santa Clara, CA) or ZES-R (Endeavor Resolute, Medtronic CardioVascular, Santa Rosa, CA) using OCT at 9 months after implantation (Figure 1). This trial was performed at 3 university hospitals in Korea.
The study protocols for the current report were separately
Patient characteristics
From December 2008 to August 2009, 51 patients who were enrolled to the study protocol were randomly assigned to an EES group (28 stents in 26 patients) or a ZES-R group (27 stents in 25 patients) (Figure 1). Among them, 7 patients were excluded because they refused to receive a follow-up angiography at 9 months. Baseline patient characteristics between the 2 groups were compared and presented in Table I. Half of the patients had ACS (5 patients [11.4%] with ST-elevation myocardial infarction
Discussion
This study was a prospective randomized trial comparing the in vivo vascular response at 9 months between ZES-R and EES using serial OCT examination. The strength of the current study is that intravascular imaging with OCT was sequentially performed on the same stents immediately after stent implantation and at 9 months after stent implantation. Our study demonstrated that the rate of strut stent coverage was similar between the 2 second-generation DESs at 9 months after stent implantation. In
Conclusion and clinical implications
This is the first prospective randomized study to compare the in vivo vascular response at 9 months between ZES-R and EES using sequential OCT examination. Our study demonstrated that strut stent coverage was comparable between the 2 second-generation DESs at 9 months after stent implantation. The rates of malapposition and thrombus were not different and quite low with both stents. This study suggested that vascular responses to ZES-R and EES at 9 months might be similarly favorable compared
Acknowledgements
The authors thank Hyun Sun Lim, PhD, of the Medical Research Support Section at Yonsei University, for statistical support.
References (21)
- et al.
Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents
J Am Coll Cardiol Cardiovasc Interv
(2010) - et al.
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial
J Am Coll Cardiol Cardiovasc Interv
(2009) - et al.
Endothelial cell recovery between comparator polymer-based drug-eluting stents
J Am Coll Cardiol
(2008) - et al.
Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation
Am J Cardiol
(2007) - et al.
Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions)
JACC Cardiovasc Interv
(2011) - et al.
Assessment of coronary arterial thrombus by optical coherence tomography
Am J Cardiol
(2006) - et al.
Intracoronary thrombus formation after drug-eluting stents implantation: optical coherence tomographic study
Am Heart J
(2010) - et al.
Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial
J Am Coll Cardiol
(2011) - et al.
Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study
J Am Coll Cardiol Cardiovasc Interv
(2010) - et al.
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
N Engl J Med
(2004)
Cited by (0)
Clinical trial registration information: Unique identifier: NCT00894062 (COVER OCT).